USPTO Art Unit 1691 Prosecution Statistics

Art Unit Information

Art Unit: 1691
Group: 1690
Tech Center: 1600
Total Cases: 1,628
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19327711METHODS OF IMPROVING LUNG FUNCTIONSeptember 2025March 2026Allow610NoNo
19327682METHODS OF IMPROVING LUNG FUNCTIONSeptember 2025March 2026Allow610NoNo
19315079S-BETA-HYDROXYBUTYRATE ESTERS FOR IMPROVING METABOLIC FUNCTIONAugust 2025January 2026Allow510NoNo
19295254FORMULATIONS OF VIMSELTINIBAugust 2025December 2025Allow400YesNo
19286812Biphenyl and Phenylpyridine CompoundsJuly 2025December 2025Allow500YesNo
19278338TOPICAL COMPOSITIONSJuly 2025February 2026Allow710NoNo
19271553GLP-1R Agonist and Therapeutic Method ThereofJuly 2025December 2025Allow501NoNo
19261853COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDSJuly 2025December 2025Allow610NoNo
19258578PHARMACEUTICAL COMPOSITIONS OF NILOTINIBJuly 2025January 2026Allow610NoNo
19250968SOLID STATE FORMSJune 2025August 2025Allow200YesNo
19250765SOLID STATE FORMSJune 2025August 2025Allow200YesNo
19249435MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDERJune 2025August 2025Allow200YesNo
19230319DIPYRIDINE BENZOTHIOPHENE DERIVATIVE COMPOUNDJune 2025July 2025Allow200NoNo
19227609METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINEJune 2025January 2026Allow810NoNo
19227593METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINEJune 2025January 2026Allow810NoNo
19224687COMPOUNDS AND THEIR USES AS CD38 INHIBITORSMay 2025January 2026Allow701NoNo
19224601CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOFMay 2025November 2025Allow510YesNo
19218087ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTSMay 2025August 2025Allow210YesNo
19215054ADVANTAGEOUS ANTI-HCV COMBINATION THERAPYMay 2025September 2025Allow410NoNo
19207954SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOFMay 2025December 2025Allow700NoNo
19206909PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEMay 2025October 2025Allow510NoNo
19205979APPLICATION OF GLYCEROL MONODECANOATE IN PREPARATION OF HYPOGLYCEMIC DRUG OR FUNCTIONAL FOODMay 2025October 2025Allow510NoNo
19196922AZITHROMYCIN PREMIX FORMULATION AND PRODUCT, METHODS OF PREPARING SAME, AND METHODS OF USING SAMEMay 2025September 2025Allow410YesNo
19193361NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOFApril 2025January 2026Allow820NoNo
19094486AZAINDOLE ROCK INHIBITORSMarch 2025May 2025Allow200NoNo
19089839INHIBITORS OF NLRP3 INFLAMMASOMEMarch 2025October 2025Allow610YesNo
19084086ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTSMarch 2025October 2025Allow710NoNo
19082283METHODS FOR TREATING CANCER, REDUCING SIDE EFFECTS OF CANCER TREATMENT, AND PREVENTING THE RECURRENCE OF CANCERMarch 2025November 2025Allow811YesNo
19079070FORMULATIONS OF VIMSELTINIBMarch 2025May 2025Allow200YesNo
19072846COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOFMarch 2025July 2025Allow510YesNo
19072656KRAS INHIBITORSMarch 2025December 2025Allow921YesNo
19070439METHODS OF IMPROVING LUNG FUNCTIONMarch 2025August 2025Allow510YesNo
19069464Cannabichromene Derivatives And Use ThereofMarch 2025July 2025Allow410NoNo
19059754Testosterone Dodecanoate Compositions and MethodsFebruary 2025November 2025Allow920NoNo
19050632TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADRELFebruary 2025February 2026Abandon1210NoNo
19026681NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOFJanuary 2025February 2026Allow1311YesNo
19030399AMINO ACID COMPOSITIONSJanuary 2025September 2025Allow810YesNo
19030439AMINO ACID COMPOSITIONSJanuary 2025September 2025Allow810NoNo
19025101CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDEJanuary 2025June 2025Allow510NoNo
19021386METHOD FOR TREATING A DISORDERJanuary 2025August 2025Allow710NoNo
19018702ILOPROST COMPOSITIONS AND FORMULATIONS THEREOFJanuary 2025July 2025Allow610YesNo
19008588DIETARY GLYCINE AND SERINE RESTRICTION FOR CANCER TREATMENTJanuary 2025June 2025Allow510YesNo
19005921USE OF TYROSOL AS A PHYSIOLOGICAL ENHANCER OF CREATINE AND ITS APPLICATION IN CONTINUOUS HIGH INTENSITY EXERCISEDecember 2024July 2025Allow620NoNo
19002520COMPOUNDS FOR ACTIVATING A SEROTONIN RECEPTORDecember 2024May 2025Allow510NoNo
18990585USE OF MARIBAVIR IN TREATMENT REGIMENSDecember 2024May 2025Allow510YesNo
18990486USE OF MARIBAVIR IN TREATMENT REGIMENSDecember 2024July 2025Allow710YesNo
18987521PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONEDecember 2024June 2025Allow610NoNo
18988131PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILEDecember 2024August 2025Allow810NoNo
18875945TRYPTAMINE DERIVATIVESDecember 2024January 2026Abandon1310NoNo
18980262TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTIONDecember 2024December 2025Allow1220NoNo
18967341WOUND TREATMENTS AND COMPOSITIONSDecember 2024September 2025Allow910NoNo
18965591METHOD OF TREATMENT WITH MILSAPERIDONEDecember 2024September 2025Allow1010YesNo
18964637GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENTDecember 2024February 2025Allow200NoNo
18958956COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMENovember 2024August 2025Allow920NoNo
18959040NOVEL PHENYLPYRAZOLE INSECTICIDE COMPOUNDS AND COMPOSITIONSNovember 2024May 2025Allow610NoNo
18952401SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2-METHYLPROPYL)AMINO)PYRIDO[3,4-D]PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOFNovember 2024October 2025Allow1120NoNo
18952791COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSNovember 2024November 2025Abandon1220NoNo
18951543PLEUROMUTILIN DERIVATIVE CONTAINING A THIAZOLO[5,4-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOFNovember 2024March 2025Allow401NoNo
18935099DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOFNovember 2024January 2025Allow200NoNo
18935253MODULATORS OF DCN-1 AND METHODS OF USE THEREOFNovember 2024January 2025Allow200NoNo
18932667PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024April 2025Allow510NoNo
18929263SELECTIVE LIGANDS FOR TAU AGGREGATESOctober 2024January 2025Allow200YesNo
18927412STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAINOctober 2024July 2025Allow811YesNo
18860494PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVESOctober 2024February 2025Allow400NoNo
18924252Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyOctober 2024January 2025Allow310NoNo
18920528HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASEOctober 2024February 2026Allow1620YesNo
18918161PTPN2/PTP1B Degrader and Therapeutic Method ThereofOctober 2024December 2024Allow200NoNo
18857747Method for Preparing Trifluoromethyl Aromatic CompoundOctober 2024June 2025Allow800YesNo
18914975AZAINDOLE ROCK INHIBITORSOctober 2024January 2025Allow400YesNo
18855893TRYPTAMINE DERIVATIVESOctober 2024March 2026Allow1720NoNo
18855563INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOFOctober 2024December 2025Allow1410NoNo
18910861HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATEROctober 2024March 2025Allow510YesNo
18910839HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATEROctober 2024February 2025Allow510YesNo
18855229AN IMPROVED PROCESS FOR THE PREPARATION OF REMIMAZOLAMOctober 2024October 2025Allow1201YesNo
18853657ACETYL SALICYLIC ACID COMPOSITION FOR INTRAVENOUS ADMINISTRATION, ITS STORAGE, PRODUCTION AND USEOctober 2024June 2025Allow810NoNo
18898132GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATESeptember 2024March 2025Allow510NoNo
18892950REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEEDSeptember 2024March 2025Allow610YesNo
18843258COMPOUND WITH BROAD-SPECTRUM ANTIBACTERIAL ACTIVITY AND ITS ANTIBACTERIAL COMPOSITIONSeptember 2024July 2025Allow1010NoNo
18813368COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEAugust 2024September 2025Allow1320YesYes
18811608PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOFAugust 2024July 2025Abandon1111NoNo
18808641COMPOUNDS FOR FGFR INHIBITIONAugust 2024February 2025Allow601NoNo
18807247SYSTEM AND METHOD FOR TRIGLYCERIDE MANUFACTUREAugust 2024June 2025Allow1011YesNo
18806346SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSESAugust 2024March 2025Allow710YesNo
18790828Dosage RegimenJuly 2024April 2025Allow910NoNo
18833747ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODSJuly 2024November 2025Allow1520NoNo
18785350PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024April 2025Allow920NoNo
18783394KRAS G12C INHIBITORSJuly 2024October 2024Allow200NoNo
18832248GINGERENONE A PRODRUGS AS SENSOTHERAPEUTICS AND METHODS OF USEJuly 2024April 2025Allow801YesNo
18778305TREATMENT OF PAIN AND VASOCONSTRICTIONJuly 2024March 2026Abandon2030NoNo
18776474MONOGLYCERIDE USE IN ANIMALSJuly 2024October 2025Allow1410NoNo
18729953SHORT-ACTING MONOAMINE RELEASERSJuly 2024December 2025Allow1711NoNo
18774065MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAMEJuly 2024August 2025Allow1310NoNo
18763277PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024September 2024Allow210NoNo
18763243COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024December 2024Allow510NoNo
18763258COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024December 2024Allow510NoNo
18751014PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024February 2025Allow810NoNo
18745509COMPOSITIONS AND METHODS FOR MODULATING EQUINE FATTY ACID PROFILESJune 2024September 2025Allow1510NoNo
18680287ESKETAMINE FOR THE TREATMENT OF DEPRESSIONMay 2024March 2025Abandon910NoNo
18679403DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATITISMay 2024August 2025Allow1521YesNo
18670619EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1120NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1691.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
7
(58.3%)
Examiner Reversed
5
(41.7%)
Reversal Percentile
84.0%
Higher than average

What This Means

With a 41.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
84
Allowed After Appeal Filing
41
(48.8%)
Not Allowed After Appeal Filing
43
(51.2%)
Filing Benefit Percentile
95.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 48.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1691 - Prosecution Statistics Summary

Executive Summary

Art Unit 1691 is part of Group 1690 in Technology Center 1600. This art unit has examined 1,628 patent applications in our dataset, with an overall allowance rate of 96.1%. Applications typically reach final disposition in approximately 28 months.

Comparative Analysis

Art Unit 1691's allowance rate of 96.1% places it in the 93% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1691 receive an average of 1.26 office actions before reaching final disposition (in the 10% percentile). The median prosecution time is 28 months (in the 63% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.